How can we make Informed Consent Forms more understandable?. At #EBMT2025 in Florence, T2EVOLVE hosted a round table on reducing unnecessary complexity of Informed Consent Forms (ICFs) for patients in clinical trials. We are proud to share highlights on the T2EVOLVE website

A sincere thank you to the T2EVOLVE Work Group for Patients and Caregivers (WGPC)!.T2EVOLVE is committed to providing patient-centered information on the innovative CAR T-cell treatment. The Work Group for Patients and Caregivers (WGPC) plays a crucial role in defining content.

Looking for patient-friendly information about CAR T-cell treatment?.The T2EVOLVE Patient Hub offers valuable information about this ground-breaking treatment, available in six different languages. Gain insights through our explainer videos for patients and caregivers. 🔗

🧬 #T2EVOLVE Round Table on ICF at #EBMT25: Reimagining Informed Consent in CAR T-cell Therapy 📝.Still buzzing from the powerful panel discussion hosted by #T2EVOLVE at #EBMT25 on the future of Informed Consent Forms  in advanced therapies! 💬💡.Clinicians, regulators, industry

T2EVOLVE is looking forward to the upcoming roundtable session at #EBMT25 on April 1 from 9:00 to 10:30 on implementing Patient-Friendly Informed Consent Forms in CAR-T Clinical Studies: Insights and Solutions. Representatives from patients, study sponsors, study investigators,

We are thrilled to share exciting updates on preclinical advancements driven by the #T2EVOLVE consortium. With a focus on innovation and collaboration, our efforts continue to bridge the gap between ground-breaking research and clinical applications in #cellulartherapy. View our

RT @VJHemOnc: What is pentanoate, and how may it be used to guide patient outcome prediction and #CARTCell engineering?. Maik Luu of @Unikl….

We would like to thank the #T2EVOLVE community for joining us for our yearly meeting at the #EHA-EBMT Meeting (#CART25) in Strasbourg, France. From achieving new milestones to holding a fruitful joint workshop with the GoCART Coalition on leveraging synergies across consortia, we

We congratulate #T2EVOLVE Project Managers Elise Pennings and Maik Luu on each receiving a 5th Emerging Investigators #EHA-EBMT Joint Fellowship Awards in the Field of Cell Therapy and Immunotherapy at #CART25 on patient reported outcomes of CAR T-cell therapy and

#T2EVOLVE aims to accelerate access to CAR T-cell Therapy across Europe. Through heartfelt patient stories, expert interviews, and resources, we offer patients an open access, central place to learn about what they can expect from this innovative treatment and how to navigate its

T2EVOLVE is proud to announce our presence at the 51st Annual Meeting of @TheEBMT in Florence, Italy. Consortium representative Carmen Sanges from the @Uniklinikum_Wue will chair and moderate a discussion on Patient-Friendly Informed Consent Forms in CAR-T Clinical Studies on

How can we accelerate development and access to immunotherapy with TCR and CAR immune cells? From the importance of #CARTtherapy to #T2EVOLVE's aims, you can now learn more about our breakthrough alliance in our new explainer video. Watch now:

#T2EVOLVE will take part in the EHA-EBMT Eutopean CAR T-cell Meeting #CART25 in STrasbourg, France. Join us for our roundtable discussion on February 7 at 17:30 as we discuss immune-related adverse outcome pathways and preclinical models. Register now:

Connect with #T2EVOLVE at the 11th @ITOCconference in Munich where Project Coordinator Michael Hudecek will be giving an update on RORing cancer with novel CAR T cell on April 5 at 10:00. View the meeting: Abstract submission for the meeting is also open.

RT @EHA_Hematology: Do you have new research on #CARTcells that you would like to share with the world? Late-breaking abstract submission f….

2024 has been a big year for #T2EVOLVE. From presentations at international meetings to offering more resources on #CARTcells to patients, we have continued working towards increased development and access to this innovative treatment. Learn more about our successes below 👇

@EHAPatient @knowyournodes @EHA_Hematology @IMFmyeloma @EuroGct @AcuteLeuk @Kersten_MJ @JulioDelgadoHem @MyelomaEurope.

What determines eligibility for #CARTcell therapy? In this informative video, a patient shares their personal story, & 3 experts explain key criteria & reasons why some patients might not qualify. Now available in 6 languages: #PatientStory #Hematology

On October 10, J Awigena-Cook, #T2EVOLVE partner from Bristol Myers Squibb for Work Packages 5 & 8, will speak at the @EMA_News Scientific Symposium on Advanced Therapy Medicinal Products - 'Contribution, evolution, revolution'. Learn more:

Microbiome-derived postbiotics can predict CAR T cell therapy outcome. Novel mechanistic insights from the microbiome-immunotherapy axis!.